How Top Pharma Are Constructing Their Next Model Of Clinical Development

By 2030, the hybrid and decentralized clinical trial (DCT) market is projected to exceed a value of $12 billion, as reported by Grandview Research. The emergence of patient-centered technology and the subsequent rise of digital and decentralized trials, catalyzed by the COVID-19 pandemic in 2020, have significantly transformed the realm of clinical research. This transformation is set to leave a lasting impact on the way clinical trials are conducted.

With the growth of the Life Science and Software-as-a-Service (SaaS) sectors, sponsors are increasingly embracing DCT platforms. Nonetheless, the true power of DCT lies not in its application to a single study but in its broad adoption across various studies and trials.

Discover how embracing the platform shift towards digital and decentralized trials while constructing the next model of clinical conduct can empower organizations to navigate the evolving landscape, deliver patient-centric trials, and achieve their organizational goals.